Abstract:INTRODUCTION AND OBJECTIVES: Docetaxel (DTX) is one of the primary drugs used for treating castration resistant prostate cancer (CRPC).Unfortunately, over time patients invariably develop resistance to DTX therapy and their disease will continue to progress.The mechanisms by which resistance develops is still incompletely understood.This study seeks to determine the involvement of miRNAs, specifically miR-181a, in DTX resistance in CRPC.METHODS: Total RNA from parental C4-2B prostate cancer cells and DTX resistant C4-2B cells (C4-2B TaxR) was submitted for small RNA deep sequencing.Data was analyzed to ascertain which miRNAs expressions were most altered in C4-2B TaxR cells compared to parental cells.Having identified an increase in miR-181a in resistant cells, its expression was modulated in C4-2B and C4-2B TaxR cells by transfecting them with miR-181a mimics or antisense, respectively.Following transfection, cell number was determined after 48 h with or without DTX.Cross resistance to cabazitaxel induced by miR-181a was also determined.Western blots were used to determine ABCB1 protein expression and rhodamine assays used to assess activity.Phospho-p53 expression was assessed by western blot and apoptosis was measured by ELISA in C4-2B TaxR cells with inhibited miR-181a expression with or without DTX.RESULTS: miR-181a is significantly upregulated in C4-2B TaxR cells compared to parental C4-2B cells as analyzed by small RNA sequencing.Overexpression of miR-181a in C4-2B cells confers DTX and cabazitaxel resistance.Knockdown of miR-181a in C4-2B TaxR cells re-sensitizes them to treatment with both DTX and cabazitaxel.miR-181a knockdown alone induced apoptosis in C4-2B TaxR cells which is further enhanced by DTX.We next assessed if miR-181a altered expression or activity of ABCB1, which is overexpressed/active in C4-2B TaxR cells and promotes resistance to DTX by pumping the drug out of cells.We found that miR-181a does not impact ABCB1 expression or activity.Since we previously demonstrated that phospho-p53 can modulate DTX sensitivity, we determined if miR-181a can alter p53 expression in C4-2B TaxR cells.Knockdown of miR-181a in C4-2B TaxR cells induced phospho-p53 expression, suggesting that miR-181a induced resistance to DTX is mediated by inhibition of phospho-p53 expression.CONCLUSIONS: Overexpression of mir-181a in C4-2B TaxR cells contributes to their resistance to DTX and inhibition of mir-181a expression can restore treatment response.This is due, in part, to modulation of p53 phosphorylation and induction of apoptosis.

Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells

Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells.

Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.

MiR-138–5p Inhibits Prostate Cancer Cell Proliferation and Chemoresistance by Targeting APOBEC3B

Microrna-323 Upregulation Promotes Prostate Cancer Growth and Docetaxel Resistance by Repressing P73

Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p/TrkB axis

MicroRNA-195 Regulates Docetaxel Resistance by Targeting Clusterin in Prostate Cancer

Establishment and Characterization of a Docetaxel-Resistant Human Prostate Cancer Cell Line.

HDAC3-mediated silencing of miR-451 decreases chemosensitivity of patients with metastatic castration-resistant prostate cancer by targeting NEDD9.

Use of Mir-145 and Testicular Nuclear Receptor 4 Inhibition to Reduce Chemoresistance to Docetaxel in Prostate Cancer

MicroRNA‑328 directly targets p21‑activated protein kinase 6 inhibiting prostate cancer proliferation and enhancing docetaxel sensitivity.

Secreted miR-210-3p, miR-183-5p and miR-96-5p reduce sensitivity to docetaxel in prostate cancer cells

MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells Via Direct Suppression of JAG1/Notch1 Axis

MP99-17 CIRCULARRNA-C17 ALTERS THE ANTI ANDROGEN-ENZALUTAMIDE RESISTANCE IN CASTRATION-RESISTANT PROSTATE CANCER VIA REGULATING ANDROGEN RECEPTOR VARIANT ARV7 EXPRESSION

LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer

NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer

MicroRNA-452 Contributes to the Docetaxel Resistance of Breast Cancer Cells

MicroRNA-21 Regulates the Sensitivity of Diffuse Large B-cell Lymphoma Cells to the CHOP Chemotherapy Regimen.

MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3.

miR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4

microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells